Current Osteoporosis Reports

, Volume 7, Issue 1, pp 23–26

Glucocorticoid-induced osteoporosis

Authors

    • Cedars-Sinai/UCLA and OMC Clinical Research Center
  • Nancy E. Lane
Article

DOI: 10.1007/s11914-009-0005-4

Cite this article as:
Silverman, S.L. & Lane, N.E. Curr Osteoporos Rep (2009) 7: 23. doi:10.1007/s11914-009-0005-4

Abstract

Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.

Download to read the full article text

Copyright information

© Current Medicine Group, LLC 2009